Corporate News
Therma Bright (THRM.V) closed its trading session unchanged, reporting a 0 % movement over the 24‑hour period ending at 08:28 AM Central Europe on Wednesday, 21 March. The share price remained steady at CAD 0.03 on the major exchanges where the stock is listed. With a total of 61.2 million shares outstanding, the company’s market capitalisation sits at approximately CAD 2.1 million. In the last 24 hours, roughly CAD 4.5 thousand worth of Therma Bright shares were traded, indicating a modest level of liquidity for the thin‑listed equity.
Recent Performance
Since the close of the previous month, Therma Bright has seen its share price decline by 22.22 %. This downturn has outpaced the broader market and underscores the company’s vulnerability in a highly competitive medical‑technology niche. The simple moving average of the last 200 trading days is currently at CAD 0.05, suggesting a long‑term downward trend that investors should monitor. Historically, the stock has reached a 52‑week high of CAD 0.11 on 12 November 2025, while the 52‑week low fell to CAD 0.04 on 19 October 2026, highlighting significant price volatility over the past year.
Peer Comparison
In the same 24‑hour window, Therma Bright’s peers exhibited a range of movements:
| Stock | Change | Current Price | Market Capitalisation |
|---|---|---|---|
| Current Water I (WATR.V) | 0 % | CAD 0.01 | CAD 2.5 million |
| Aurwest | +30 % | CAD 0.20 | CAD 2.4 million |
| E‑power (EPR.CN) | 0 % | CAD 0.03 | CAD 2.4 million |
| Kingsview Minerals (KVM.CN) | –6.82 % | CAD 0.41 | CAD 2.4 million |
| Archon Minerals (ACS.V) | 0 % | CAD 0.04 | CAD 2.5 million |
While Aurwest experienced a sharp 30 % rally, Therma Bright remained flat, suggesting that the company’s recent performance is less influenced by sector‑wide momentum and more by its own fundamentals.
Company Overview
Therma Bright Inc. is a medical technology firm focused on the development of thermal therapeutic devices aimed at treating insect stings, bites, and preventing cold sores. The company’s product pipeline is built around proprietary heat‑based treatments that leverage controlled temperature exposure to accelerate healing and mitigate discomfort. Despite the niche market, competition from larger dermatological and pharmaceutical players remains a challenge.
Outlook
Analysts view Therma Bright’s current valuation—priced at a mere few cents per share—as attractive for long‑term investors who believe in the company’s therapeutic approach. However, the recent 22 % decline in share price and low trading volume signal caution. A sustained recovery will likely depend on product launches, regulatory approvals, and the company’s ability to differentiate itself from established competitors. Investors should therefore weigh the potential upside against the inherent risk associated with a thin‑liquidity, high‑volatility stock.
